A new Cholesterol lowering drug from Novartis is hailed as "Life Changing". It's been just approved in the UK. Global trials have proved that this drug safely cuts cholesterol by 50%.
The drug is "Inclisiran", and it is administered as an injection. It boosts the liver’s ability to reduce levels of low-density lipoprotein (LDL) cholesterol, known as “bad” cholesterol. This drug is deemed to a game changer.
It's a double-stranded, small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes.
It's the first of a drug family that uses RNA interference to help the body remove harmful cholesterol from the bloodstream. It does this by silencing a gene called PCSK9, which instructs the body to produce a protein that helps regulate the amount of cholesterol in the blood. By turning off this gene, Inclisiran helps the liver absorb more LDL cholesterol from the blood and break it down.
Following a single subcutaneous administration of 284 mg inclisiran, LDL-C reduction was apparent within 14 days post-dose. Mean reductions of 49-51% for LDL-C were observed 30 to 60 days post-dose. At day 180, LDL-C levels were still reduced by approximately 53%.
Inclisiran may also be a convenient, effective option for people who have not seen satisfactory reductions in their cholesterol levels with drugs called statins, as well as for people who cannot take this type of drug.
Furthermore, when inclisiran is combined with a statin, researchers predict a 75–80% reduction in cholesterol levels.
The under-the-skin jab will be administered twice annually.
The drug is "Inclisiran", and it is administered as an injection. It boosts the liver’s ability to reduce levels of low-density lipoprotein (LDL) cholesterol, known as “bad” cholesterol. This drug is deemed to a game changer.
It's a double-stranded, small interfering ribonucleic acid (siRNA), conjugated on the sense strand with triantennary N-acetylgalactosamine (GalNAc) to facilitate uptake by hepatocytes.
It's the first of a drug family that uses RNA interference to help the body remove harmful cholesterol from the bloodstream. It does this by silencing a gene called PCSK9, which instructs the body to produce a protein that helps regulate the amount of cholesterol in the blood. By turning off this gene, Inclisiran helps the liver absorb more LDL cholesterol from the blood and break it down.
Following a single subcutaneous administration of 284 mg inclisiran, LDL-C reduction was apparent within 14 days post-dose. Mean reductions of 49-51% for LDL-C were observed 30 to 60 days post-dose. At day 180, LDL-C levels were still reduced by approximately 53%.
Inclisiran may also be a convenient, effective option for people who have not seen satisfactory reductions in their cholesterol levels with drugs called statins, as well as for people who cannot take this type of drug.
Furthermore, when inclisiran is combined with a statin, researchers predict a 75–80% reduction in cholesterol levels.
The under-the-skin jab will be administered twice annually.
